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Abstract
Background: Nitric oxide (NO) produced in macrophages plays a pivotal role as a leishmanicidal agent. A previous
study has demonstrated that 20% of the L. (V.) braziliensis isolated from initial cutaneous lesions of patients from
the endemic area of Corte de Pedra, Bahia, Brazil, were NO resistant. Additionally, 5 to 11% of the patients did not
respond to three or more antimony treatments” (refractory patients). The aim of this study is to investigate if there
is an association between the resistance of L. (V.) braziliensis to NO and nonresponsiveness to antimony therapy
and cytokine production.
Methods: We evaluated the in vitro toxicity of NO against the promastigotes stages of L. (V.) braziliensis isolated
from responsive and refractory patients, and the infectivity of the amastigote forms of these isolates against human
macrophages. The supernatants from Leishmania infected macrophage were used to measure TNF-a and IL-10
levels.
Results: Using NaNO2 (pH 5.0) as the NO source, L. (V.) braziliensis isolated from refractory patients were more NO
resistant (IC50 = 5.8 ± 4.8) than L. (V.) braziliensis isolated from responsive patients (IC50 = 2.0 ± 1.4). Four isolates
were selected to infect human macrophages: NO-susceptible and NO-resistant L. (V.) braziliensis isolated from
responsive and refractory patients. NO-resistant L. (V.) braziliensis isolated from refractory patients infected more
macrophages stimulated with LPS and IFN-g at 120 hours than NO-susceptible L. (V.) braziliensis isolated from
refractory patients. Also, lower levels of TNF-a were detected in supernatants of macrophages infected with
NO-resistant L. (V.) braziliensis as compared to macrophages infected with NO-susceptible L. (V.) braziliensis (p < 0.05
at 2, 24 and 120 hours), while no differences were detected in IL-10 levels.
Conclusion: These data suggest that NO resistance could be related to the nonresponsiveness to antimony
therapy seen in American Tegumentary Leishmaniasis.
Background
Leishmaniasis is a parasitic disease considered a major
public health problem affecting 88 countries throughout
Europe, Asia, Africa and America, with an annual
incidence of 1 to 1.5 million of cases, and 350 million
exposures according to the World Health Organization.
Specifically in Brazil, the Ministry of Health reports an
annual incidence of around 28.000 cases. American Tegu-
mentary Leishmaniasis (ATL) presents with a spectrum of
clinical manifestations, including cutaneous (CL), mucosal
(ML), disseminated (DL) and diffuse cutaneous leishmania-
sis (DCL). The major species that cause ATL in the New
World are L. (Viannia) braziliensis, L. (V.) guyanensis,
L. (Leishmania) amazonensis and L. (L.) mexicana [1]. In
the Northeast region of Brazil, CL, ML and DL are caused
most often by L. (V.) braziliensis; and DCL is most often
caused by L. amazonensis in the New World [2]. The
typical clinical manifestation of cutaneous leishmaniasis
(CL) is a single ulcerated lesion with elevated borders,
frequently located on the inferior limbs [3]. ML is a
destructive disease that predominantly affects the
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nasopharynx. It is most common in the areas of L. (V.) bra-
ziliensis transmission and usually occurs months or years
after CL [4]. DL is characterized by multiple pleomorphic
acneiform, papular or nodular cutaneous lesions in two or
more noncontiguous areas of the body [5].
Leishmania is a digenetic protozoa with two different
life forms: promastigotes and amastigotes. Flagellated
promastigotes replicate and mature to the infectious
metacyclic form in the gut of sand flies. Promastigotes
are transmitted to mammalian host by the bite of
infected sand fly vector, which injects parasites into the
host skin where they undergo facilitated phagocytosis by
a macrophage and subsequently transform to obligate
intracellular amastigotes [6,7]. Murine models have
taught us that type 1 cell-mediated immune responses
are key to immune protection against Leishmania spp.
infections [8]. Interleukin (IL)-12 is an important cyto-
kine that is produced by macrophages early in the infec-
tion. IL-12 induces interferon-gamma (IFN-g)
production by the T helper 1 (TH1) and NK cells [9]. In
murine systems, IFN-g has been shown to act in synergy
with another macrophage derived cytokine, tumor
necrosis factor alpha (TNF-a), in activating macro-
phages and leading to the expression of inducible nitric
oxide synthase (iNOS). iNOS catalyzes the synthesis of
nitric oxide (NO) from arginine, a potent microbicidal
agent that leads to killing of intracellular parasites and
other microbes [10-12]. Our laboratory has described
some L. (V.) braziliensis strains with resistance to NO
Moreover, there is an association between the size of
the initial cutaneous lesion of ATL and NO susceptibil-
ity of the parasite isolate in vitro. Furthermore, patients
infected with NO-resistant L. braziliensis presented with
larger cutaneous lesions than patients infected with NO-
susceptible L. braziliensis [13].
The pentavalent antimonials (SbV) meglumine anti-
moniate and stibogluconate have been the drugs of
choice to treat leishmaniasis for decades [14]. The
mechanism of SbV action is unclear. A general consen-
sus is that SbV acts upon several targets in the parasite,
including inhibition of parasite glycolysis, fatty acid
beta-oxidation and ADP phosphorylation [15-17]. SbV is
most like reduced by the host cells to the trivalent form
prior to its intracellular action (SbIII) [18]. L. infantum
axenic amastigotes have been shown to undergo SbIII-
mediated DNA fragmentation, suggesting that apoptosis
may participate in the mechanism of antimonial action
[19]. Moreover, treatment of visceral leishmaniasis with
pentavalent antimonials induces reactive oxygen species
and NO generation in L. donovani-infected macrophages
[20]. The emergence of antimony-resistant (SbR) visceral
leishmaniasis (VL) in various parts of the world [21] has
severely compromised the ability to control the disease.
At the Corte de Pedra Health Post, located in an
endemic area for cutaneous leishmaniasis situated in the
southeast region of the state of Bahia, Brazil, the inci-
dence of the disease is 8,1/1000 habitants. A study
defining phenotypic variations of parasite isolates at the
point of clinical diagnosis could allow us to predict the
evolution and the outcome of disease. Therefore, we
evaluated phenotypic differences amongst L. (V.) brazi-
liensis isolates from patients who did or did not respond
to antimony therapy. Our data suggests that NO resis-
tance could be related to the nonresponsiveness of
American Tegumentary Leishmaniasis to antimony
therapy.
Methods
Parasites and Patients recruiting
The patients described in this manuscript are from the
endemic area of Corte de Pedra. Every 15 days our
group travels to this population to treat leishmaniasis
and other diseases. Patients are submitted for routine
diagnostic evaluations that include parasite isolation and
blood collection for serological purposes. All human
subjects were briefed on procedures and signed
informed consent documentation. All work with human
subjects was carried out under Maternidade Climério de
Oliveira Ethical Committee approval number 5/2006. L.
(V.) braziliensis parasites were obtained by needle
aspiration of the skin lesions in patients with ATL
before therapy. Parasites were speciated by isoenzyme
electrophoresis and monoclonal antibodies at the Depar-
tamento de Bioquímica e Biologia Molecular, Instituto
Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil [22].
Responsive and refractory patients
Subjects with ATL were identified and diagnosed at the
Corte de Pedra Health Post, Bahia, Brazil. We analyzed
1640 cutaneous leishmnaisis cases from Corte de Pedra,
between 2001 and 2003, and found that 5% of the
patients needed 3 courses of antimony treatment to heal
their lesions, and 11% of the CL cases were refractory to
more than 3 courses of antimony treatment. For this
present study, patients who healed their lesions with
one course of antimony therapy (20 mg SbV/kg/day dur-
ing twenty days) were considered responsive patients.
Patients who received three or more courses of anti-
mony therapy were considered refractory patients. The
interval between the courses of treatment was 60 days.
Sixteen parasite isolates were studied in total: eight were
isolated from responsive patients (Table 1) and eight
were isolated from refractory patients (Table 2).
Isolation and cultivation of L. (V.) braziliensis
Parasites isolates L. (V.) braziliensis were initially culti-
vated in tubes with biphasic medium (NNN) consisting
of rabbit blood agar overlaid with liver infusion tryptose
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(LIT), supplemented with 10% heat inactivated fetal
bovine serum medium (Sigma Chemical Co., St. Louis,
MO). Following isolation, these parasites were cryopre-
served. After selection for the present study, parasite
cultures were expanded in Schneider’s insect medium
(Sigma) pH 7.2 supplemented with 10% fetal bovine
serum (FBS) and 2% human male urine at 25°C (com-
plete Schneider medium).
Evaluation of NO susceptibility of L. (V.) braziliensis
promastigotes by MTT assay
The virulence of Leishmania spp. is highest in the sta-
tionary phase, a growth phase that is enriched for the
infectious metacyclic stage of the organism. The sensi-
tivity of MTT uptake assays, however, is best using log
phase parasites. We previously reported that MTT
assays of oxidant sensitivity of log phase cultures corre-
lates with oxidant sensitivity and virulence of the same
isolate when it reaches stationary phase growth [23,24].
Two hundred μL of L. (V.) braziliensis promastigotes
isolated from responsive (n = 8) or refractory patients
(n = 8) in log phase growth at 2.5 × 107 parasites/mL in
Hanks’ balanced solution (HBSS, Sigma, pH 5.0) were
exposed to dilutions of NaNO2 (NO donor) from 0 to
16 mM. After 4 hours at 25°C, plates were centrifuged
and parasites were incubated with 5 mg of MTT/mL
[3-(4,5-dimethylthyazol)-2,5-diphenyltetiazoliumbro-
mide] at 25°C for 4 hours. Reactions were stopped with
0.04 N HCl in isopropanol and conversion of yellow
MTT to purple formazan, indicating mitochondrial
metabolism, was detectable at 540 nm. The percentage
of viability was calculated by comparison to MTT con-
centrations in wells without NaNO2 [23]. At least 3
separate NO toxicity assays were performed on each
parasite isolate.
Macrophages culture
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from six different healthy human donors. Briefly,
heparinized blood was diluted 1:2 with 0.15 M NaCl,
and separated on a Ficoll Hypaque gradient (LSM;
Organon Teknika corporation, Durham, NC, USA).
Mononuclear cells were collected from the interface
between the plasma and the Ficoll. Washed mononuc-
lear cells were suspended in RPMI 1640, 10% heat inac-
tivated AB serum (Sigma), penicillin/streptomycin
(complete medium) (Gibco BRL, Grant Island, NY). One
× 106 cells in 200 μL allowed to adhere to 8-well Lab
Tek plates for 2 hours at 37°C, 5% CO2. Non-adherent
cells were removed by rinsing, and the resultant
adherent monocytes were allowed to differentiate to
monocyte-derived macrophages over six days at 37°C in
5% CO2.
Macrophage infections
Macrophages were infected by using four of the above
described L. (V.) braziliensis promastigotes in the
stationary growth phase, 2 isolated from antimony
responsive patients (LTCP 15171 and 15404) and 2 iso-
lated from antimony refractory patients (LTCP 393 and
15344). Growth curves of these L. braziliensis isolates
were performed and no statistically significant differ-
ences were observed between the isolates used for
macrophage infection. Promastigotes were grown to the
stationary phase, washed by centrifugation, suspended in
RPMI 1640 and used to infect macrophages from
healthy donors. In each experiment, the macrophages
were infected with NO susceptible and NO resistant
parasites. Care was taken to infect macrophages from
the same individual with NO-resistant and NO-suscepti-
ble strains. The infections were done at a parasite/
macrophage ratio of 5:1 for 2 hours at 35°C in 5% CO2.
Extracellular parasites were then removed by gentle
washing, and infected macrophages were maintained
for an additional 2, 24, 72 and 120 hours. Conditions
Table 1 Optical density of L. (V.) braziliensis isolated from
responsive patients to antimony therapy exposed to
NaNO2
Isolates NaNO2 (mM)
0 0.25 0.5 1 2 4 8 16
14048 0.401 0.194 0.214 0.206 0.095 0.086 0.071 0.089
14207 0.397 0.361 0.330 0.350 0.242 0.106 0.094 0.082
14806 0.301 0.379 0.339 0.186 0.086 0.044 0.019 0.005
15171 0.401 0.316 0.238 0.165 0.088 0.056 0.040 0.045
15404 0.585 0.459 0.353 0.385 0.383 0.208 0.174 0.178
15468 0.493 0.312 0.232 0.241 0.259 0.109 0.085 0.063
15492 0.396 0.321 0.237 0.228 0.098 0.071 0.047 0.059
15826 0.296 0.125 0.149 0.128 0.120 0.084 0.081 0.082
Values represent means from three experiments for each parasite isolate. Bold
face is used to mark the isolates chosen for further studies, illustrated in
Figure 2.
Table 2 Optical density of L. (V.) braziliensis isolated from
refractory patients to antimony therapy exposed to
NaNO2
Isolates NaNO2 (mM)
0 0.25 0.5 1 2 4 8 16
393 0.531 0.534 0.585 0.614 0.536 0.458 0.366 0.283
14119 0.474 0.354 0.387 0.358 0.230 0.163 0.114 0.121
14758 0.436 0.367 0.355 0.389 0.353 0.228 0.145 0.138
14808 0.451 0.447 0.517 0.408 0.341 0.227 0.171 0.138
14933 0.475 0.428 0.437 0.353 0.192 0.168 0.135 0.154
15028 0.420 0.294 0.383 0.415 0.244 0.122 0.120 0.104
15226 0.409 0.412 0.370 0.432 0.327 0.223 0.133 0.138
15344 0.382 0.232 0.171 0.249 0.183 0.078 0.053 0.056
Values represent means from three experiments for each isolate. Bold face is
used to mark the isolates chosen for further studies, illustrated in Figure 3.
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did or did not contain LPS (100 ng/mL) plus IFN-g
(10 ng/mL), added at thirty minutes before the infection.
Cells were stained with Giemsa and the infection levels
were enumerated microscopically. Each isolate was
tested in at least three separate assays. Macrophages
from the six healthy donors were used for the infection
assays by all the selected isolates. Although the number
of parasite samples selected for macrophage infections is
small, these data clearly characterize the differences in
the behavior between the parasites with different to NO
susceptibilities previously described by our group [13].
The proportion of infected cells and the number of
parasite/100 macrophages were enumerated by three
independent observers, blinded to the experimental
conditions.
Cytokine determination
The supernatants from cultures were harvested at 2, 24,
72 and 120 hours post infection and stored at -20°C for
TNF-a and IL-10 determination by sandwich ELISA
technique (TNF-a: R&D Systems, Minneapolis, MN; IL-
10: BD-Pharmingen). A standard curve was generated
using recombinant TNF-a and recombinant IL-10 to
express the results in pg/mL.
Statistical analysis
Mann-Whitney test was used to compare susceptibility/
resistance to NO between L. (V.) braziliensis isolates.
One-way ANOVA with Tukey’s test to compare the
levels of cytokines released from infected macrophages.
Kruskal-Wallis test, Dunn’s multiple comparison Test
was used to compare the means obtained from infection
and multiplication of L. (V.) braziliensis in human
macrophages.
The analyses were done on GraphPad Prism 3.03
software (San Diego, CA, USA).
A p value < 0.05 was considered as the cutoff for
statistical significance.
Results
L. (V.) braziliensis isolated from refractory patients were
more resistant to NO than L. (V.) braziliensis isolated from
responsive patients
We compared the resistance to NO against the respon-
siveness to antimony therapy of L. (V.) braziliensis isolates
from patients. We investigated the NO toxicity by measur-
ing the viability of log phase organisms exposed to a gradi-
ent of the NO-generating agent NaNO2. Viability was
measured according to the ability of the parasites to
convert MTT to formazan, a measure of mitochondrial
activity (Tables 1 and 2). L. (V.) braziliensis isolated from
antimony-refractory patients were more resistant to NO
in vitro than L. (V.) braziliensis isolated from antimony-
responsive patients. The average IC50 (50% inhibitory
concentration) was 2.0 ± 1.4 mM NaNO2 for isolates
from susceptible, compared to 5.8 ± 4.8 mM NaNO2 for
isolates from resistant subjects (Figure 1). Defining
4 mM NaNO2 as intermediate and > 4 mM NaNO2 as
resistant, only 2 of the 8 isolates from antimony-respon-
sive subjects were intermediate and 6 of the 8 were
susceptible. This is in contrast to isolates from anti-
mony-resistant subjects, amongst which 5 of the 8 iso-
lates were either intermediate or resistant and only 3 of
8 isolates were susceptible. These data suggest that
NO-resistance might be associated with some cases of
resistance to antimony therapy.
Infection of human macrophages with L. (V.) braziliensis
isolates from patients that were responsive or refractory
to antimony therapy
To assess whether macrophage infection was influenced
by NO resistance and/or antimony responsiveness, we
selected four of the above isolates, one susceptible and
one intermediate-to-resistant each from the antimony-
responsive and the antimony-refractory groups [LTCP
15344 (NO-susceptible) and LTCP 393 (NO-resistant)
isolated from refractory patients; LTCP 15171 (NO-sus-
ceptible) and LTCP 15404 (NO-resistant) isolated from
responsive patients]. Parasites were used to infect
human monocyte-derived macrophages (MDMs) from
three different healthy donors. After 2, 24, 72 or 120
hours of infection the parasite load was quantified
microscopically to assess entry and survival in macro-
phages. Data using isolates from antimony-responsive
patients are shown in Figure 2. After 24 hours of
infection, NO-susceptible L. (V.) braziliensis infected
more macrophages than the NO-resistant parasites
Figure 1 IC50 of NaNO2. L. (V.) braziliensis isolated from antimony-
refractory patients were more resistant to the NO-generating
compound NaNO2 than L. (V.) braziliensis isolated from responsive
patients. Eight isolates each from refractory or responsive subject
were tested for susceptibility or resistance to NaNO2 using the MTT
assay. Lines mean median (* = p = 0.038, Mann-Whitney test). Lb =
L. (V.) braziliensis.
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(Figure 2A). However, at 120 hours the two isolates
had similar levels of infection. When expressed as the
percentage of infected macrophages, there was a
trend toward increased infection by NO-susceptible
L. (V.) braziliensis which did not reach statistical signifi-
cance (Figure 2B). To evaluate whether NO resistance is
manifested by resistance to macrophage leishmanicidal
activity, we infected macrophages with L. (V.) brazilien-
sis isolated from responsive patients after LPS and IFN-g
(Figure 2C and 2D). There was little difference between
the infection levels at any time point, suggesting that
NO-resistance or susceptibility does not make these
L. (V.) braziliensis isolates responsive to leishmanicidal
activity by MDMs exposed to strong activators of classi-
cal activation.
MDM infection with L. (V.) braziliensis isolated from
antimony-refractory patients showed similar results. The
NO-susceptible parasites infected more macrophages at
24 hours of infection compared to the NO-resistant
parasites, although the difference was not statistically
significant (Figure 3A-B). In contrast to isolates from
antimony-responsive subjects, after 120 hours of
infection NO-resistant L. (V.) braziliensis from anti-
mony-refractory patients achieved a significantly higher
burden of infection than NO-susceptible isolates (53 ±
14 amastigotes/100 macrophages). The addition of LPS
plus IFN-g did not affect the results (Figures 3C-D).
Overall these results indicate that NO-susceptible
isolates achieve a high level of initial infection but
are rapidly killed over 120 hrs, whereas NO-resistant
isolates either maintain the original infection level
(Figure 2) or increase infection (Figure 3).
TNF-a production is not induced in macrophages infected
with NO-resistant L. (V.) braziliensis
TNF-a is a proinflammatory cytokine important for the
intracellular control of Leishmania infection [11]. We
evaluated whether TNF-a production is impaired during
infection with NO-resistant (LTCP 393 and LTCP
15404) compared to NO-susceptible (LTCP 15171 and
LTCP 15344) L. (V.) braziliensis isolates from antimony-
refractory or antimony-responsive patients. TNF-a levels
were measured in supernatants from infected macro-
phages cultures.
Figure 2 Infection of human macrophages with L. (V.) braziliensis (NO-susceptible - open bars and NO-resistant - closed bars) isolated
from patients who responded to antimony therapy. A and B, Monocyte-derived macrophages were infected with L. (V.) braziliensis
promastigotes (5:1 ratio). At 2, 24, 72 and 120 h of culture(A) the number of intracellular amastigotes and (B) the percentage of infected cells
was quantified microscopically as described in Methods. (C) and (D) Monocyte-derived macrophages were treated with LPS (100 ng/mL) plus
IFN-g (10 ng/mL) thirty minutes before infection with L. (V.) braziliensis promastigotes. At 2, 24, 72 and 120 h of culture, (C) the number of
intracellular amastigotes and (D) the percentage of infected cells was quantified microscopically. Each bar represents the mean ± SEM infection
level in MDMs from three donors (Kruskal-Wallis test, Dunn’s multiple comparison Test, * = p < 0.05).
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Non-stimulated macrophages did not produce TNF-a
at a level that differed significantly from medium when
they were infected with NO-susceptible and NO-resistant
L. (V.) braziliensis. The positive control stimulation, LPS
+ IFN-g, led to a significant increase of TNF-a produc-
tion at all time points (Figure 4A). However, macro-
phages that were stimulated with LPS and IFN-g 30 min
prior to infection with NO-susceptible L. (V.) braziliensis
produced significantly more TNF-a at all time points
tested (2 h: 1954 ± 397; 24 h: 5101 ± 424; 72 h: 4766 ±
260; 120 h: 5407 ± 141), when compared to macrophages
infected with NO-resistant isolates (2 h: 804 ± 193;
24 h: 1986 ± 347; 72 h: 2233 ± 842; 120 h: 1244 ± 252) or
uninfected control (Figure 4B). The results are expressed
as mean ± standard error of mean in pg/mL. These
data suggest that NO-resistant L. (V.) braziliensis do
not induce TNF-a production by macrophages whereas
NO-susceptible isolates induces significant TNF-a
production.
IL-10 production is not altered in macrophages infected
with L (V) braziliensis isolated from refractory patients
IL-10 is a cytokine that suppresses NO-production in
macrophages. We therefore inquired whether the NO-
resistant isolates suppressed TNF-a through enhanced
IL-10 production. There were no statistically significant
differences in IL-10 production in non-stimulated
macrophages (Figure 5A). There was a trend toward
increased IL-10 in the presence of LPS + IFN-g 72 hrs
after stimulation (11 ± 5 pg/mL), suggesting a secondary
compensatory increase as has been observed in prior
reports [25]. Paradoxically, in the constant presence of
LPS + IFN-g, macrophages infected with NO-susceptible
L. (V.) braziliensis produced higher levels of IL-10
(24 h: 86 ± 48; 72 h: 52 ± 40; 120 h: 21 ± 19) than
non-infected macrophages (1 pg/mL in all time points)
or macrophages infected with NO-resistant L. (V.) brazi-
liensis (approximately 1 pg/mL in all time points). How-
ever, statistically significant differences were not found
(Figure 5B). These data suggest it is likely that another
suppressor mechanism is responsible for the enhanced
growth of NO-resistant parasites isolated from antimony
refractory patients. It seems that these parasites do not
activate macrophage to produce either TNF-a or IL-10,
while NO-susceptible induce both cytokines.
Discussion
Nitric oxide (NO) generated through the activity of the
inducible nitric oxide synthase (iNOS) is a critical com-
ponent of intracellular killing of Leishmania in murine
macrophages and clearance of disease in mice [26,27].
More recently, the importance of NO in the microbial
Figure 3 Infection of human macrophages with L. (V.) braziliensis (NO-susceptible - open bars and NO-resistant-closed bars) isolated
from patients who were refractory to antimony therapy. (A) and (B) Monocyte-derived macrophages were infected with L. (V.) braziliensis
promastigotes (5:1 ratio). At 2, 24, 72 and 120 h of culture the number of intracellular amastigotes(A) and the percentage of infected cells (B)
was quantified microscopically as described in Methods. (C) and (D) Monocyte-derived macrophages were treated with LPS (100 ng/mL) plus
IFN-g (10 ng/mL) thirty minutes before the infection with L. (V.) braziliensis promastigotes. At 2, 24, 72 and 120 h of culture, (C) the number of
intracellular amastigotes and (D) the percentage of infected cells was quantified microscopically. Each bar represents the mean ± SEM parasite
loads in MDMs from three donors (Kruskal-Wallis test, Dunn’s multiple comparison Test, * = p < 0.05).
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defenses of human macrophages against both Leishmania
spp. and Mycobacterium tuberculosis has been suggested
[28,29]. Recent data from our group demonstrated that
NO resistance of human L. (V.) braziliensis isolates corre-
lates directly with the initial size of the cutaneous lesion.
Thus, patients infected with NO-resistant Leishmania
present with a larger initial lesion size than patients
infected with NO-resistant Leishmania [13]. L. (V.) brazi-
liensis is a cause of cutaneous, mucosal and disseminated
cutaneous leishmaniasis in endemic regions. Although
some of these cutaneous lesions respond immediately to
antimony treatment, other infections can be difficult to
cure and require multiple courses of therapy [30,31].
We hypothesized that there may be inherent biological
differences between the parasites isolates causing anti-
mony-responsive versus antimony-refractory cutaneous
lesions. The purpose of the current study was to evalu-
ate phenotypic differences between L. (V.) braziliensis
isolates from patients with localized cutaneous leishma-
niasis who did or did not respond to antimony therapy.
Sensitivity of L. (V.) braziliensis parasite isolates to
nitric oxide was measured using the MTT assay as a
measure of viability after exposure to acidified NaNO2, a
compound that releases NO and induces leishmanicidal
activity [32]. We observed that more of the L. (V.) brazi-
liensis isolates from antimony-refractory patients were
NO resistant than L. (V.) braziliensis isolates derived
from antimony-responsive patients. Furthermore, all the
highly NO-resistant isolates were obtained from anti-
mony-refractory patients.
Evaluation of human macrophage infections with NO-
susceptible or NO-resistant isolates from either anti-
mony-responsive or antimony-refractory patients also
demonstrated that there are biological differences
between the isolates, which correlate with NO suscept-
ibility. NO-susceptible parasites exhibited transient
Figure 4 TNF-a production is impaired in macrophages infected with NO-resistant L. (V.) braziliensis. Monocyte-derived macrophages
were infected with NO-susceptible or NO-resistant L. (V.) braziliensis. After 2, 24, 72 or 120 h of infection the culture supernatants were harvest
from non-stimulated macrophages (A) or macrophages treated with LPS (100 ng/mL) plus IFN-g (10 ng/mL) thirty minutes prior to the addition
of parasites (B). TNF-a levels were determined by ELISA. Each bar represents the mean ± SEM of three experiment from three separate donors
(ANOVA, Tukey’s multiple comparison Test, * = p < 0.05).
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initial growth in macrophages followed by intracellular
killing, but only with a significant difference in NO-sen-
sitive isolate from an antimony-responsive patient. The
NO-resistant L. (V.) braziliensis isolates tested herein
did not exhibit the initial growth phase or intracellular
killing. Indeed, the highly NO-resistant isolate from an
antimony-refractory patient displayed significant intra-
cellular growth by 120 hrs of infection, even in the pre-
sence of LPS and IFN-g, compounds that usually
activate macrophages to become leishmanicidal [26,33].
The fact that both NO-susceptible and NO-resistant
L. (V.) braziliensis isolates were maintained out to
120 hours of macrophage infection, even in the presence
of LPS and IFN-g (Figure 2), suggests that isolates can
be resistant to other leishmanicidal mechanisms, includ-
ing products of the NADPH oxidase (hydrogen perox-
ide, superoxide) [34-36].
It was previously reported that an isolate of L. infan-
tum resistant to trivalent antimony (SbIII) in vitro was
also resistant to an exogenous NO donor and to intra-
cellular killing in activated macrophages [18]. Pentava-
lent antimony (SbV) must be reduced to SbIII to exhibit
its leishmanicidal activity [18,19]. SbIII in turn induces
the production of reactive oxygen and nitrogen radicals
in macrophages infected with L. donovani [20]. It fol-
lows logically that there may be a direct association
between non-responsiveness to antimony therapy and
NO resistance. Whether these isolates are also resistant
to hydrogen peroxide and superoxide must still be
tested. It has been demonstrated in Leishmania
donovani that the parasite uses a cascade of enzymes
that include cytosolic tryparedoxin peroxidase (cTXNPx)
for the detoxification of peroxides, a mechanism neces-
sary for the survival of digenetic parasites living in two
disparate biological environments. The exposure of the
parasite to a combination of H2O2 and nitric oxide
resulted in a significant reduction of cTXNPx levels
accompanied by high cell death. However, overexpres-
sion of cTXNPx by transfection increased the virulence,
parasite burden in macrophages and resistance to clear-
ance by antimony therapy, suggesting that differential
expression of cTXNPx is linked to parasite resistance
and virulence. [37].
The ability of L. (V.) braziliensis isolates to sustain
infection may be related to their ability to resist NO
toxicity [38]. Since arginine is a substrate of both iNOS
Figure 5 IL-10 production not is altered in macrophages infected with isolated from refractory patients. Monocyte-derived macrophages
were infected with NO-susceptible and NO-resistant L. (V.) braziliensis. After 2, 24, 72 or 120 h of infection the culture supernatants of
unstimulated macrophages (A) or from macrophages treated with LPS (100 ng/mL) plus IFN-g (10 ng/mL) for thirty minutes before infection (B),
were assessed for IL-10 levels by ELISA. Each bar represents the mean ± SEM infection levels in MDMs from three separate donors.
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and arginase, and the amount of arginine substrate is
rate-limiting for both enzymes, consumption of arginine
by the parasite can alter the activity of either enzyme in
the intracellular environment. Arginase-mediated L-argi-
nine hydrolysis produces polyamines which promote the
growth of Leishmania [39,40], whereas arginine metabo-
lism through NOS leads to toxic NO production.
L. amazonensis produce nitric oxide synthase (NOS), at
especially high levels in the axenic amastigote stage [41],
and all Leishmania species studied make arginase [40].
The presence of either enzyme could deplete environ-
mental arginine, generating either compartmentalized
NO not available to kill Leishmania or generating polya-
mines that stimulate parasite growth [42]. Overactivity
of either parasite enzyme would sequester arginine away
from host. In addition to suppressing its synthesis
through scavenging substrate, Leishmania may inhibit
NO generation indirectly by inhibiting the macrophage
synthesis of IL-12, decreasing the amount of IFN-g pro-
duced by T and other cells, and in turn down-regulating
the amount of NO produced through classical macro-
phage activation [43].
Using supernatants from culture of macrophages
infected with NO-susceptible and NO-resistant L. (V.)
braziliensis, we determined that macrophages stimulated
with LPS and IFN-g produced significantly lower
amounts of TNF-a when they were infected with
NO-resistant L. (V.) braziliensis than when they were
infected with NO-susceptible L. (V.) braziliensis at all
time points measured. This result suggests that
NO-resistant L. (V.) braziliensis do not induce TNF-a
production by macrophages.
TNF-a is a proinflammatory cytokine produced by
macrophages and lymphocytes and it is important in
the control of Leishmania spp. infections [11]. The
impairment of TNF-a production by NO-resistant
L. (V.) braziliensis is consistent with the finding that
these isolates are present in patients with a severe form
of tegumentary leishmaniasis [44].
Leishmania parasites can induce the production
and/or secretion of various immunosuppressive signaling
molecules including arachidonic acid metabolites and
the cytokines TGF-b and IL-10 [45]. IL-10 in turn sup-
presses IFN-g and TNF-a, and consequently inhibits
NO-production by macrophages [46]. As a first step in
examining mechanisms of TNF-a suppression, we
examined whether IL-10 was induced by NO-resistant
L. (V.) braziliensis. Disproving our hypothesis, we
observed minimal IL-10 production by non-stimulated
macrophages infected with NO-susceptible and NO-
resistant L. (V.) braziliensis. Paradoxically, when macro-
phages were stimulated with LPS and IFN-g and infected
with NO-susceptible L. (V.) braziliensis they produced
high levels of IL-10, whereas macrophages infected with
NO-resistant L. (V.) braziliensis produced minimal. We
interpret this as a compensatory increase in IL-10 in
response to the increased type 1 cytokines induced, illu-
strated by the TNF-a increase observed in Figure 4.
These results show that enhanced IL-10 is not the
mechanism leading to absence of TNF-a production in
macrophages infected with NO-resistant L. (V.) brazi-
liensis. It is likely that another mechanism generates the
immunosuppressive signal delivered by the resistant
parasites. Candidates would include PGE2, which favors
parasite intracellular survival by suppressing TNF-a,
IL-1 and reactive oxygen intermediates [47], and the
cytokine TGF-b whose production correlates with
diminished iNOS expression [48-52].
Conclusion
The data presented in this report suggest that resistance
of human L. (V.) braziliensis isolates to NO is associated
with nonresponsiveness to antimony therapy and an
impaired macrophage activation to produce TNF-a.
Together with our previously published data indicating
that NO resistance is associated with a worsened clinical
presentation of American Tegumentary Leishmaniasis,
these data suggest there may be consequences of NO
resistance relevant to human disease. These observations
may serve as a basis to test clinical isolates for resistance
to toxic oxidants as a predictor of the course and drug-
responsiveness of disease.
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